Navigation Links
IDM Pharma Announces Compliance With NASDAQ Minimum Bid Price Requirements
Date:2/20/2008

IRVINE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it received notification from The NASDAQ Stock Market that the Company has regained compliance with NASDAQ Marketplace Rule 4450(a)(5), which requires listed companies to maintain a closing bid price of at least $1.00 per share.

On February 19, 2008, the closing price of the Company's common stock was $3.14 per share.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's ability to comply with the minimum bid price requirements under the NASDAQ Marketplace Rules. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to maintain a closing bid price of $1.00 per share or higher and risks relating to the Company's ability to comply with other NASDAQ requirements. Other risks affecting the Company and its drug development programs are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
2. Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism
3. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
4. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
5. Halleland Health Consulting Assists PBMs in Achieving URAC Accreditation for Pharmacy Benefit Management
6. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
7. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
8. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
9. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
10. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
11. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... Beach, Florida (PRWEB) , ... July 25, 2017 ... ... employee, Jennifer Haller, to the sales department joining as Regional Account Manager for ... relationships with contracted customers in the liquidation of their obsolete medical assets. , ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... and finance management services to communities across North Carolina, is launching a charity ... to raise community support for the ongoing fight against bladder cancer. , The ...
(Date:7/25/2017)... ... 25, 2017 , ... Dr. Donna Bergman, professor of education ... published an article in the medical science journal Physical Medicine and Rehabilitation titled ... and the research that helped produce it, were written and conducted in collaboration ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... as medical director. Dr. Negrette has more than a decade of experience in ... worked closely with individuals fighting addictions, eating disorders, psychotic and manic conditions, as ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... for its Product Innovation in the prestigious CEO World Awards®. The coveted annual ... new products and services, CEO case studies, corporate social responsibility, and milestones from ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... 2017 Did you know that PhRMA member companies invested ... combined spending on brand medicines, generics and the supply chain account ... for just half of this (7 percent)? Or that ... world,s venture capital investments in high-growth biopharmaceutical startups? ... The ...
(Date:7/17/2017)... 17, 2017  MedX Holdings, Inc., the manufacturer and ... and rehabilitation equipment, today announced the national roll out ... considered the gold standard for the treatment of low ... strengthening equipment. How ... physician or practice who prescribe the MedX Home Back ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
Breaking Medicine Technology: